https://www.selleckchem.com/pr....oducts/dl-ap5-2-apv.
mpared with previous dosing methods. Using EHRs, a satisfactory popPK model was verified and adopted to develop a web-based individual dose optimization interface. The interface is expected to improve treatment outcomes of IV vancomycin for severe infections among critically ill neonates. This study provides the foundation for a cohort study to demonstrate the utility of the new approach compared with previous dosing methods. Identifying patients at risk of hereditary cancer based on their family health history is a highly nuanced
Like
Comment
Share
